This page is an unofficial mirror and is not legal advice. Verify the document against the official source before relying on it.
HB1292: expanding the right to try act to include certain qualifying severe illness and permitting certain regenerative stem cell therapies under the act.
Bill details
No mirrored bill text is available for this bill yet. Use the official source links below for the full current record.
Last sync warning: curl exited 52: curl: (52) Empty reply from server
Version history, amendments, and roll-call votes were not present in the imported local bill data.
Official links
Extraction diagnostics
Related law links
RSA references from bill data
-
126-Z
· amend
· effective 2027-01-01
l and qualifying severe illness. This chapter shall be construed consistently with the general court's stated purpose. 5 New Section; Regenerative Stem Cell Therapies. Amend RSA 126-Z by inserting after section 8 the following new section: 126-Z:9 Regenerative Stem Cell Therapies. I. A physician may perform stem cell therapy that is not approved by the United States Food and Drug Administrati
-
126-Z:1
· amend
· effective 2027-01-01
lls, tissues, or cellular or tissue-based products, the state will advance regenerative medicine in a manner consistent with the values of this state. 2 Right to Try Act. Amend RSA 126-Z:1 through 126-Z:4 to read as follows: 126-Z:1 Definitions. In this chapter: I. "Eligible facility" means a licensed New Hampshire institution that is operating under a Federalwide Assurance ("FWA") for the Protec
-
126-Z:3
· reference
· effective 2027-01-01
evice [to eligible patients pursuant to this chapter. A manufacturer may] not approved by the FDA available to patients if the manufacturer and patient satisfy the requirements of RSA 126-Z:3, II. Pursuant to this chapter, a manufacturer may: (a) Provide [an investigational] a drug, biologic, or device to [an eligible] a patient without receiving compensation. (b) Require [an eligible] a patient to pay
-
126-Z:6
· amend
· effective 2027-01-01
or court for injunctive relief and reasonable attorney's fees against any regulatory or law enforcement authority that violates this chapter. 3 Telehealth Prescreening. Amend RSA 126-Z:6, I to read as follows: I. Notwithstanding any regulation or provision of law to the contrary, any health care provider, while physically located in New Hampshire, may conduct a telehealth prescreening with any patie
-
126-Z:8
· amend
· effective 2027-01-01
escreening with any patient, in any state or jurisdiction, who has been diagnosed by a physician with a terminal or qualifying severe illness. 4 Statutory Construction. Amend RSA 126-Z:8 to read as follows: 126-Z:8 Statutory Construction. The general court enacts this chapter to promote maximum access by removing barriers in state law and indemnifying those involved in providing potentially life-sav
-
126-Z:9
· reference
· effective 2027-01-01
ss” means an illness that is both chronic and debilitating. A qualifying severe illness shall include any condition treated with stem cell therapy pursuant to the requirements of RSA 126-Z:9. III-b. "Chronic and debilitating" shall have the same meaning as "severely debilitating" as defined under 21 CFR section 312.81(b). IV. "Remote signing" means the signing of any form, witnessed by a notary publi
-
151
· reference
· effective 2027-01-01
to this chapter. II. Notwithstanding any provision of law to the contrary, the department of health and human services shall not take action against a facility licensed under RSA 151 based primarily on the institution's participation in the treatment or use of [an investigational] a drug, biologic, or device under this chapter. III. Notwithstanding any provision of law to the contrary, a manufac
-
329
· reference
· effective 2027-01-01
withstanding any provision of law to the contrary, the board of medicine shall not revoke, fail to renew, or take any other action against a physician's license issued pursuant to RSA 329 based primarily on a physician's recommendation to [an eligible] a patient regarding or prescription for or treatment with [an investigational] a drug, biologic, or device pursuant to this chapter. II. Notwithstandi
-
329:17
· reference
· effective 2027-01-01
stitutional Review Board; and (b) "Off-label use" means prescribing an FDA approved drug, biologic, or device for a use not approved for that specific indication consistent with RSA 329:17, VI-b. III. "Physician" means the licensed allopathic or osteopathic physician who is providing medical care or treatment to the[ eligible] patient for the terminal or qualifying severe illness. III-a. “Qualifying
RSAs mentioned by this document
- RSA 126-Z · RIGHT TO TRY ACT
- RSA 151 · RESIDENTIAL CARE AND HEALTH FACILITY LICENSING
- RSA 329 · PHYSICIANS AND SURGEONS
- RSA 126-Z:1 · Definitions
- RSA 126-Z:3 · Liability of Physician; Facility
- RSA 126-Z:6 · Telehealth Prescreening
- RSA 126-Z:8 · Statutory Construction
- RSA 329:17 · Disciplinary Action; Remedial Proceedings